Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Henlius BiotechFRA:2E8 -2.67%50 OCF Yield % is 3.91 as of Aug. 16, 2026, which is 21% above its 10-year median of 3.24. GuruFocus rates FRA:2E8 with a GF Score™ of 50/100 and a GF Value™ of €3.38 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,411 Biotechnology companies, Shanghai Henlius Biotech ranks better than 89.09% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Shanghai Henlius Biotech OCF Yield % Related Terms
Shanghai Henlius Biotech OCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2E8 vs VRTX, REGN, RVMD: OCF Yield % Comparison
For the Biotechnology subindustry, Shanghai Henlius Biotech's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Henlius Biotech OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Henlius Biotech's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Shanghai Henlius Biotech's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Henlius Biotech (FRA:2E8) has a OCF Yield % of 3.91 as of Aug. 16, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Shanghai Henlius Biotech and its competitors. This is 21% above median its historical median of 3.24. According to the industry distribution chart, Shanghai Henlius Biotech ranks #154 out of 1411 companies in the Biotechnology industry, placing it in the top 10.9%.
Is Shanghai Henlius Biotech's OCF Yield % too high?
Shanghai Henlius Biotech's current OCF Yield % of 3.91 is 21% above median its 10-year median of 3.24. Based on the distribution chart, Shanghai Henlius Biotech ranks #154 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai Henlius Biotech has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Henlius Biotech's OCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Henlius Biotech ranks #154 out of 1411 companies for OCF Yield %. This places Shanghai Henlius Biotech in the top 11% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Shanghai Henlius Biotech and its competitors. Shanghai Henlius Biotech's current OCF Yield % is 3.91, which is 21% above median its own 10-year median of 3.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Henlius Biotech stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Henlius Biotech (FRA:2E8) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.38, compared to a current price of €7.30 — trading 116% above its estimated fair value. The current OCF Yield % is 3.91, which is 21% above median its 10-year median of 3.24. Shanghai Henlius Biotech's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Shanghai Henlius Biotech (FRA:2E8), the current OCF Yield % is 3.91 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Henlius Biotech (FRA:2E8) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Henlius Biotech stock appears to be overvalued.
The current stock price of €7.30 is trading 116% above its estimated GF Value™ of €3.38.
GuruFocus considers Shanghai Henlius Biotech to be Significantly Overvalued.
Key valuation signals for FRA:2E8:
OCF Yield %: 3.91 (21% above median its 10-year median of 3.24)
GF Value™: €3.38 vs. price of €7.30 (116% above fair value)
No single metric tells the full story. See the FRA:2E8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China, Asia Pacific (excluding Mainland China), North America, South America, Oceania, and Europe. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
50GF Score
Get the complete analysis for FRA:2E8
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2E8 has been successfully added to your 
